Compare Analog Devices, Inc. (ADI) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Analog Devices, Inc. vs Crispr Therapeutics AG — how do they compare? Analog Devices, Inc. trades at $391 (market cap $187.67B), while Crispr Therapeutics AG trades at $53.9 (market cap $5.23B). The key difference: Analog Devices, Inc. is far larger — about 35.9× Crispr Therapeutics AG's market cap, and Analog Devices, Inc. pays a 1.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ADI | CRSP | |
|---|---|---|
Market Cap | $187.67B | $5.23B |
Sector | Technology | Health |
52-Week High | $445.48 | $76.78 |
52-Week Low | $225.20 | $44.34 |
Enterprise Value | $192.92B | $3.65B |
Dividend Yield | 1.14% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
